More biotechs join S&P300 index
Friday, 05 September, 2003
Market analyst Standard and Poor's has added four more Australian biotechnology firms and a medical device company to its S&P300 index.
Circadian Technologies, Genetic Technologies, Metabolic Pharmaceuticals and Norwood Abbey, along with retractable syringe specialist Unitract, will join the index from September 19.
Tim Eisenhauer, S&P's head of index services, said companies were selected to join the index on the basis if the free float of their shares, on their market capitalisation, and their liquidity over a six-month period.
The last healthcare firm to join the 300 was artificial heart maker Ventracor.
The S&P300's healthcare board also includes Agenix, Cellestis, Chemeq, Cochlear, CSL, IDT, Novogen, Peptech, ResMed and Sirtex.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
